Dianthus Therapeutics Stock Analysis

DNTH Stock   23.66  1.02  4.13%   
Dianthus Therapeutics is fairly valued with Real Value of 22.89 and Target Price of 24.0. The main objective of Dianthus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dianthus Therapeutics is worth, separate from its market price. There are two main types of Dianthus Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dianthus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Dianthus Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Dianthus Stock Analysis Notes

About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Dianthus Therapeutics was currently reported as 11.51. The company recorded earning per share (EPS) of 7.22. Dianthus Therapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 12th of September 2023. To learn more about Dianthus Therapeutics call Marino MBA at 929 999 4055 or check out https://dianthustx.com.

Dianthus Therapeutics Quarterly Total Revenue

2.17 Million

Dianthus Therapeutics Investment Alerts

Dianthus Therapeutics generated a negative expected return over the last 90 days
Dianthus Therapeutics has high historical volatility and very poor performance
Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 2.83 M. Net Loss for the year was (43.55 M) with profit before overhead, payroll, taxes, and interest of 6.42 M.
Dianthus Therapeutics generates negative cash flow from operations
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Dianthus Therapeutics, Inc. Sees Large Growth in Short Interest - MarketBeat

Dianthus Therapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dianthus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
8th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Dianthus Largest EPS Surprises

Earnings surprises can significantly impact Dianthus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-04
2022-06-30-0.34-0.290.0514 
2021-08-05
2021-06-30-0.3725-0.320.052514 
2020-11-05
2020-09-30-0.43-0.370.0613 
View All Earnings Estimates

Dianthus Therapeutics Environmental, Social, and Governance (ESG) Scores

Dianthus Therapeutics' ESG score is a quantitative measure that evaluates Dianthus Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Dianthus Therapeutics' operations that may have significant financial implications and affect Dianthus Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Dianthus Therapeutics Thematic Classifications

In addition to having Dianthus Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Dianthus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 700.27 M.

Dianthus Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.24)(0.25)
Return On Capital Employed(0.28)(0.30)
Return On Assets(0.24)(0.25)
Return On Equity(0.26)(0.27)

Management Efficiency

Dianthus Therapeutics has return on total asset (ROA) of (0.1896) % which means that it has lost $0.1896 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2599) %, meaning that it created substantial loss on money invested by shareholders. Dianthus Therapeutics' management efficiency ratios could be used to measure how well Dianthus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.25. The current Return On Capital Employed is estimated to decrease to -0.3. As of now, Dianthus Therapeutics' Non Currrent Assets Other are increasing as compared to previous years. The Dianthus Therapeutics' current Other Assets is estimated to increase to about 146.1 K, while Total Assets are projected to decrease to under 112.5 M.
Last ReportedProjected for Next Year
Book Value Per Share 32.77  38.91 
Tangible Book Value Per Share 32.77  38.91 
Enterprise Value Over EBITDA 1.62  1.70 
Price Book Value Ratio 0.32  0.30 
Enterprise Value Multiple 1.62  1.70 
Price Fair Value 0.32  0.30 
Enterprise Value-78.1 M-74.2 M
Understanding the operational decisions made by Dianthus Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin
(13.77)
Return On Assets
(0.19)
Return On Equity
(0.26)

Technical Drivers

As of the 6th of December, Dianthus Therapeutics shows the Standard Deviation of 3.95, coefficient of variation of (2,323), and Mean Deviation of 2.93. Dianthus Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Dianthus Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Dianthus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Dianthus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Dianthus Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dianthus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dianthus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dianthus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Dianthus Therapeutics Predictive Daily Indicators

Dianthus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dianthus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Dianthus Therapeutics Corporate Filings

F3
3rd of December 2024
An amendment to the original Schedule 13D filing
ViewVerify
13A
22nd of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
8th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
8K
7th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
24th of October 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
21st of October 2024
Other Reports
ViewVerify
11th of October 2024
Other Reports
ViewVerify

Dianthus Therapeutics Forecast Models

Dianthus Therapeutics' time-series forecasting models are one of many Dianthus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dianthus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Dianthus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dianthus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dianthus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dianthus Therapeutics. By using and applying Dianthus Stock analysis, traders can create a robust methodology for identifying Dianthus entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(15.41)(16.18)
Operating Profit Margin(17.05)(17.90)
Net Loss(15.41)(16.18)
Gross Profit Margin 0.87  0.92 

Current Dianthus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dianthus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dianthus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
24.0Strong Buy11Odds
Dianthus Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Dianthus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dianthus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dianthus Therapeutics, talking to its executives and customers, or listening to Dianthus conference calls.
Dianthus Analyst Advice Details

Dianthus Stock Analysis Indicators

Dianthus Therapeutics stock analysis indicators help investors evaluate how Dianthus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dianthus Therapeutics shares will generate the highest return on investment. By understating and applying Dianthus Therapeutics stock analysis, traders can identify Dianthus Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow15.4 M
Common Stock Shares Outstanding5.2 M
Total Stockholder Equity168.9 M
Property Plant And Equipment Net800 K
Cash And Short Term Investments173.7 M
Cash132.3 M
Accounts Payable2.6 M
Net Debt-131.7 M
50 Day M A26.5596
Total Current Liabilities9.6 M
Other Operating Expenses51 M
Non Current Assets TotalM
Non Currrent Assets Other1.1 M
Stock Based Compensation2.9 M

Complementary Tools for Dianthus Stock analysis

When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
CEOs Directory
Screen CEOs from public companies around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins